Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Breast Cancer Res
; 21(1): 146, 2019 12 18.
Article
in En
| MEDLINE
| ID: mdl-31852484
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Tetrahydronaphthalenes
/
Breast Neoplasms
/
Receptors, Estrogen
/
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
/
Cyclin-Dependent Kinase 4
/
Cyclin-Dependent Kinase 6
Limits:
Animals
/
Female
/
Humans
Language:
En
Year:
2019
Type:
Article